Literature DB >> 22712682

Newborn screening shows a high incidence of sickle cell anemia in Central India.

Dipty L Jain1, Vijaya Sarathi, Dipty Upadhye, Rohini Gulhane, Anita H Nadkarni, Kanjaksha Ghosh, Roshan B Colah.   

Abstract

There is limited data on the incidence of sickle cell anemia in Central India; we therefore conducted a study to estimate the incidence of this disease in Central India. Mothers who delivered a live baby at the Government Medical College, Nagpur, India were screened for the presence of the sickle cell hemoglobin {Hb S: [β6 (A3) Glu→Val, GAG>GTG]} using the solubility test within 48 hours of delivery. Infants of mothers who showed the presence of Hb S then underwent Hb analysis by high performance liquid chromatography (HPLC). A total of 8243 mothers was screened, 1178 of whom were positive. One thousand, one hundred and sixty-two infants of mothers with a positive solubility test underwent Hb analysis by HPLC; 530 infants were normal, while 536 were heterozygous for Hb S (sickle cell trait), 88 babies were homozygous for Hb S (sickle cell anemia), while another eight babies had other Hb abnormalities. The incidence of sickle cell anemia was highest in the Scheduled caste group (1:50). We concluded that the incidence of sickle cell anemia is high in central India.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22712682     DOI: 10.3109/03630269.2012.691434

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  15 in total

1.  Newborn screening for sickle cell disease in India: the need for defining optimal clinical care.

Authors:  Jyotish Patel; Graham R Serjeant
Journal:  Indian J Pediatr       Date:  2013-09-14       Impact factor: 1.967

2.  Knowledge, awareness, and attitude of premarital screening with special focus on sickle cell disease: a study from Odisha.

Authors:  Basanta Kumar Bindhani; Naorem Kiranmala Devi; Jayanta Kumar Nayak
Journal:  J Community Genet       Date:  2020-06-18

3.  Paper-based microchip electrophoresis for point-of-care hemoglobin testing.

Authors:  Muhammad Noman Hasan; Arwa Fraiwan; Ran An; Yunus Alapan; Ryan Ung; Asya Akkus; Julia Z Xu; Amy J Rezac; Nicholas J Kocmich; Melissa S Creary; Tolulope Oginni; Grace Mfon Olanipekun; Fatimah Hassan-Hanga; Binta W Jibir; Safiya Gambo; Anil K Verma; Praveen K Bharti; Suchada Riolueang; Takdanai Ngimhung; Thidarat Suksangpleng; Priyaleela Thota; Greg Werner; Rajasubramaniam Shanmugam; Aparup Das; Vip Viprakasit; Connie M Piccone; Jane A Little; Stephen K Obaro; Umut A Gurkan
Journal:  Analyst       Date:  2020-03-03       Impact factor: 4.616

4.  Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.

Authors:  Meghna Dua; Halima Bello-Manga; Yvonne M Carroll; Aisha Amal Galadanci; Umma Abdulsalam Ibrahim; Allison A King; Ayobami Olanrewaju; Jeremie H Estepp
Journal:  Expert Rev Hematol       Date:  2022-04-12       Impact factor: 2.819

5.  The spectre of race in American medicine.

Authors:  Mariam O Fofana
Journal:  Med Humanit       Date:  2013-08-29

6.  Micro mapping the frequencies of beta thalassemia and sickle cell anemia in India: A way forward to plan control strategies.

Authors:  Reena Das
Journal:  Indian J Hum Genet       Date:  2012-05

7.  Sickle cell disease in tribal populations in India.

Authors:  Roshan B Colah; Malay B Mukherjee; Snehal Martin; Kanjaksha Ghosh
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

8.  Morbidity pattern of sickle cell disease in India: a single centre perspective.

Authors:  Sanjay Tewari; David Rees
Journal:  Indian J Med Res       Date:  2013-09       Impact factor: 2.375

9.  Sickle cell disease in India: A perspective.

Authors:  Graham R Serjeant; Kanjaksha Ghosh; Jyotish Patel
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

Review 10.  Evolving locally appropriate models of care for indian sickle cell disease.

Authors:  Graham R Serjeant
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.